Arkolith/Insider Trading/LGND/Form 4

Espinoza Octavio

Chief Financial OfficerLIGAND PHARMACEUTICALS INC (LGND) · full profile →Form 4 · filed May 28, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 27, 2026Option exercise(M)764$63.62$49K27K
May 27, 2026Option exercise(M)972$52.84$51K28K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 27, 2026Option exercise(M)972—$00
May 27, 2026Option exercise(M)764—$017K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002001011-26-000071) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML